JPS57130914A - Prolongation of activity retention - Google Patents

Prolongation of activity retention

Info

Publication number
JPS57130914A
JPS57130914A JP56015254A JP1525481A JPS57130914A JP S57130914 A JPS57130914 A JP S57130914A JP 56015254 A JP56015254 A JP 56015254A JP 1525481 A JP1525481 A JP 1525481A JP S57130914 A JPS57130914 A JP S57130914A
Authority
JP
Japan
Prior art keywords
active substance
cyclodextrin polymer
vessel
membrane
permeable membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP56015254A
Other languages
Japanese (ja)
Inventor
Kazuaki Harada
Satoshi Morimoto
Keishiro Tsuda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institute of Advanced Industrial Science and Technology AIST
Original Assignee
Agency of Industrial Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency of Industrial Science and Technology filed Critical Agency of Industrial Science and Technology
Priority to JP56015254A priority Critical patent/JPS57130914A/en
Priority to US06/343,214 priority patent/US4432802A/en
Publication of JPS57130914A publication Critical patent/JPS57130914A/en
Pending legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2989—Microcapsule with solid core [includes liposome]

Abstract

PURPOSE:A vessel made of permeable membrane is filled with a clathrate complex consisting of an active substance and a cyclodextrin polymer of such a molecular weight as it cannot pass through the membrane and sealed tightly to keep a constant activity for a long period of time. CONSTITUTION:A vessel at least partially made of a permeable membrane is filled with a clathrate complex consisting of an active substance and a cyclodextrin polymer of such a high molecular weight as it cannot pass through the membrane and sealed tightly. The permeable membrane is made of cellulose or acetylcellulose preferably. An example of the active substance is a drug, agricultural chemical or flavor and the amount is generally 0.05-0.20pts.wt. per 1pt. of the cyclodextrin polymer. Since said polymer does not diffuse toward the outside of the vessel, the dissociation into the active substance and the cyclodextrin polymer is slow and a constant level of activity is kept for a long period of time.
JP56015254A 1981-02-04 1981-02-04 Prolongation of activity retention Pending JPS57130914A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP56015254A JPS57130914A (en) 1981-02-04 1981-02-04 Prolongation of activity retention
US06/343,214 US4432802A (en) 1981-02-04 1982-01-27 Inclusion compound-containing composite

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP56015254A JPS57130914A (en) 1981-02-04 1981-02-04 Prolongation of activity retention

Publications (1)

Publication Number Publication Date
JPS57130914A true JPS57130914A (en) 1982-08-13

Family

ID=11883713

Family Applications (1)

Application Number Title Priority Date Filing Date
JP56015254A Pending JPS57130914A (en) 1981-02-04 1981-02-04 Prolongation of activity retention

Country Status (2)

Country Link
US (1) US4432802A (en)
JP (1) JPS57130914A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61152765A (en) * 1984-12-27 1986-07-11 Nippon Ekishiyou Kk Synthetic resin product including compound clathrated with cyclodextrin
JPS6215A (en) * 1985-02-26 1987-01-06 Fujisawa Pharmaceut Co Ltd Sustained release pharmaeutical containing 2-nitroxymethyl-6-chloropyridine or clathrate compound thereof in beta-cyclodextrin
JPS61291984A (en) * 1985-06-18 1986-12-22 Ichiro Shibauchi Production of rustproof material
JPS6327502A (en) * 1986-07-22 1988-02-05 Agency Of Ind Science & Technol Cyclodextrin-silica composite material and production thereof
US4925678A (en) * 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
US5707604A (en) * 1986-11-18 1998-01-13 Access Pharmaceuticals, Inc. Vivo agents comprising metal-ion chelates with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles
US5672334A (en) * 1991-01-16 1997-09-30 Access Pharmaceuticals, Inc. Invivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans
US5114719A (en) * 1987-04-29 1992-05-19 Sabel Bernhard A Extended drug delivery of small, water-soluble molecules
ZA885069B (en) * 1987-07-24 1989-03-29 Fujisawa Pharmaceutical Co Sustained-release percutaneous preparations
JPH0269540A (en) * 1988-09-05 1990-03-08 Chisso Corp Crystalline polyolefin composition
US5075432A (en) * 1989-08-11 1991-12-24 Edward Vanzo Spherical cyclodextrin polymer beads
CA2066616A1 (en) * 1990-10-01 1992-04-02 Masanobu Yoshinaga Cyclodextrin polymer and cyclodextrin membrane prepared using said polymer
US6106866A (en) * 1995-07-31 2000-08-22 Access Pharmaceuticals, Inc. In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites
DE19734244A1 (en) * 1997-08-07 1999-02-11 Wacker Chemie Gmbh A composition comprising a complex of cyclodextrin with isothiazolinone in a water-soluble shell and its use
US6653524B2 (en) 1999-12-23 2003-11-25 Kimberly-Clark Worldwide, Inc. Nonwoven materials with time release additives
KR100785913B1 (en) * 2006-11-29 2007-12-17 한국과학기술연구원 Polymerized beta-cyclodextrin powder and its preparation method
CA2692211C (en) 2009-12-14 2011-09-13 Cellresin Technologies, Llc Maturation or ripening inhibitor release from polymer, fiber, film, sheet or packaging
US10182567B2 (en) 2011-03-27 2019-01-22 Cellresin Technologies, Llc Cyclodextrin compositions, articles, and methods
RU2559463C2 (en) 2011-03-27 2015-08-10 СЕЛЛРЕЗИН ТЕКНОЛОДЖИЗ, ЭлЭлСи Cyclodextrin-based composition, thereof-containing packaging material and method of its obtaining
US9320288B2 (en) 2012-11-30 2016-04-26 Cellresin Technologies, Llc Controlled release compositions and methods of using
US9421793B2 (en) 2014-06-26 2016-08-23 Cellresin Technologies, Llc Electrostatic printing of cyclodextrin compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH445129A (en) * 1964-04-29 1967-10-15 Nestle Sa Process for the preparation of high molecular weight inclusion compounds
GB1538075A (en) * 1975-03-24 1979-01-10 Champion Paper Co Ltd Formation of microcapsules by interfacial cross-linking and microcapsules produced thereby
JPS55130909A (en) * 1979-03-31 1980-10-11 Agency Of Ind Science & Technol Granular material containing active substance and having inactive surface-protecting layer, and its preparation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives

Also Published As

Publication number Publication date
US4432802A (en) 1984-02-21

Similar Documents

Publication Publication Date Title
JPS57130914A (en) Prolongation of activity retention
GB1425685A (en) Sterility analyzer
EP0147464A4 (en) Chemically active aqueous solution and solid substance containing ferrous ion.
KR970703175A (en) Method of Manufacturing and Storing Solutions
AU589678B2 (en) Gelatine capsules and process for their manufacture
ES8201596A1 (en) their preparation and use as medicines.
GB1422854A (en) Hollow filament encapsulating therein enzyme microorganism or both and preparation thereof
HUT47570A (en) Insecticides containing as active substance 3-substituated-1-/chlor-tiasole-5-il-methil/-2-nitroamin-1,3-diaza-cycloalkans and process for production of the active substances
ES8202349A1 (en) Polymer articles containing entrapped volatile ingredients.
GB1456930A (en) Foams and sponge sheet for cigar manufacture
EP0161681A3 (en) Gel plate and process for preparing same
IE893810L (en) Stabilizing packaged iodophor and minimizing leaching of¹iodine through packaging
US3095307A (en) Deoxygenating method and product
NL188527C (en) METHOD FOR PREPARING A MEDICINAL PRODUCT CONTAINING A DIMETHOXYCHINAZOLINE, FORMED MEDICINAL PRODUCT WITH ANTI-BLOOD PRESSURE EFFECT AND METHOD FOR PREPARING THE ACTIVE SUBSTANCE
IE871040L (en) Butter aroma composition
GB1377618A (en) Composition and device for impelementing the delivery storage and use of microorganisms
MY104654A (en) Osmotic absorbents.
IE780784L (en) Tea bags
JPS52156932A (en) Remedy for diabetes
GB8310812D0 (en) Microporous powders
GB1441320A (en) Method of removing bacteria and water droplets from a gas stream
Garg et al. The synthesis of the 1-N-(L-aspart-4-oyl) glucosylamine linkage. New synthesis of 1-N-(L-aspart-1-and 4-oyl)-4-O-beta-D-galactopyranosyl-beta-D-glucopyranosylamines
FR2233930A1 (en) Container to maintain a constant humidity - has water retained within covered compartments to maintain cheese in main part non-dry
Levin The content of components of the fibrinolytic system in the platelets of donor and fibrinolytic blood
JPS54151184A (en) Washed cell body mixture